Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbot Medical ( (MBOT) ) has shared an announcement.
On April 30, 2026, Microbot Medical announced the appointment of Alon Tamir as Vice President of Sales for Europe, the Middle East and Asia, marking a key step in its international growth strategy. While continuing to prioritize commercialization of its FDA-cleared LIBERTY Endovascular Robotic System in the U.S., the company is building regulatory, operational and commercial capabilities to support entry into major global markets.
Tamir, a veteran of the medical technology sector, will lead a comprehensive EMEA sales strategy that includes go-to-market planning, distribution and strategic partnerships, and market-specific product launches. The move follows LIBERTY’s limited and then full market release in the U.S. and is underpinned by strong physician interest and a large peripheral endovascular procedure volume in Europe, positioning Microbot to accelerate expansion beyond its home market.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is a single-use, remotely operated robotic solution designed to enhance precision, efficiency and safety in endovascular care, backed by a broad intellectual property portfolio.
The company targets the peripheral endovascular market, where it sees substantial global procedure volumes comparable between Europe and the U.S. By prioritizing innovation in endovascular robotics and leveraging regulatory clearances such as FDA approval, Microbot aims to drive adoption of its technology in both domestic and international markets.
Average Trading Volume: 2,131,548
Technical Sentiment Signal: Strong Sell
Current Market Cap: $137M
For an in-depth examination of MBOT stock, go to TipRanks’ Overview page.